Avantax Advisory Services Inc. Increases Stock Position in Zoetis Inc. (NYSE:ZTS)

Avantax Advisory Services Inc. boosted its stake in Zoetis Inc. (NYSE:ZTSGet Rating) by 4.2% during the 3rd quarter, Holdings Channel reports. The firm owned 4,448 shares of the company’s stock after buying an additional 179 shares during the quarter. Avantax Advisory Services Inc.’s holdings in Zoetis were worth $660,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of ZTS. Fairfield Bush & CO. purchased a new stake in Zoetis in the 1st quarter worth $134,000. Sequoia Financial Advisors LLC increased its holdings in shares of Zoetis by 5.3% in the 1st quarter. Sequoia Financial Advisors LLC now owns 4,166 shares of the company’s stock worth $786,000 after buying an additional 211 shares during the last quarter. Candriam Luxembourg S.C.A. increased its holdings in shares of Zoetis by 3.9% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 51,581 shares of the company’s stock worth $9,727,000 after buying an additional 1,914 shares during the last quarter. Covestor Ltd increased its holdings in shares of Zoetis by 102.8% in the 1st quarter. Covestor Ltd now owns 724 shares of the company’s stock worth $137,000 after buying an additional 367 shares during the last quarter. Finally, Merit Financial Group LLC increased its holdings in shares of Zoetis by 92.8% in the 1st quarter. Merit Financial Group LLC now owns 2,342 shares of the company’s stock worth $442,000 after buying an additional 1,127 shares during the last quarter. Hedge funds and other institutional investors own 90.23% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $163.81 on Monday. The company has a current ratio of 2.27, a quick ratio of 1.48 and a debt-to-equity ratio of 1.12. The company has a market capitalization of $76.35 billion, a price-to-earnings ratio of 37.40, a PEG ratio of 2.82 and a beta of 0.73. The firm’s 50-day moving average is $150.72 and its 200 day moving average is $156.81. Zoetis Inc. has a 12 month low of $124.15 and a 12 month high of $205.30.

Zoetis (NYSE:ZTSGet Rating) last issued its earnings results on Thursday, November 3rd. The company reported $1.21 EPS for the quarter, missing analysts’ consensus estimates of $1.24 by ($0.03). The company had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.08 billion. Zoetis had a return on equity of 48.41% and a net margin of 25.82%. Zoetis’s revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.25 earnings per share. Research analysts predict that Zoetis Inc. will post 4.87 EPS for the current year.

Zoetis Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 1st. Shareholders of record on Friday, January 20th will be paid a $0.375 dividend. This is an increase from Zoetis’s previous quarterly dividend of $0.33. This represents a $1.50 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date is Thursday, January 19th. Zoetis’s dividend payout ratio is currently 34.25%.

Analyst Ratings Changes

ZTS has been the topic of a number of research reports. JPMorgan Chase & Co. reduced their target price on shares of Zoetis from $250.00 to $225.00 and set an “overweight” rating on the stock in a report on Monday, October 17th. StockNews.com initiated coverage on shares of Zoetis in a report on Wednesday, October 12th. They issued a “buy” rating on the stock. William Blair restated an “outperform” rating on shares of Zoetis in a report on Thursday, November 3rd. Morgan Stanley reduced their target price on shares of Zoetis from $264.00 to $248.00 and set an “overweight” rating on the stock in a report on Tuesday, November 15th. Finally, The Goldman Sachs Group cut their price target on shares of Zoetis from $207.00 to $180.00 and set a “buy” rating on the stock in a report on Friday, November 4th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Zoetis presently has a consensus rating of “Moderate Buy” and an average price target of $215.17.

About Zoetis

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSGet Rating).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.